Andrew Phillips

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Sign-in to see full Profile

Sign-in to see all Coauthors

Publications

TOP 3
Rodger Alison J; Fox Zoe; Lundgren Jens D; Kuller Lewis H; Boesecke Christoph; Gey Daniela; Skoutelis Athanassios; Goetz Matthew Bidwell; Phillips Andrew N;
Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.
Cozzi-Lepri Alessandro; Phillips Andrew N; Martinez-Picado Javier; Monforte Antonella d'Arminio; Katlama Christine; Eg Hansen Ann-Brit; Horban Andrzej; Bruun Johann; Clotet Bonaventura; Lundgren Jens D;
Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.
Bower Mark; Fisher Martin; Hill Teresa; Reeves Iain; Walsh John; Orkin Chloe; Phillips Andrew N; Bansi Loveleen; Gilson Richard; Easterbrook Philippa; Johnson Margaret; Gazzard Brian; Leen Clifford; Pillay Deenan; Schwenk Achim; Anderson Jane; Porter Kholoud; Gompels Mark; Sabin Caroline A;
CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Andrew Phillips (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2009: Rodger Alison J; Fox Zoe; Lundgren Jens D; Kuller Lewis H; Boesecke Christoph; Gey Daniela; Skoutelis Athanassios; Goetz Matthew Bidwell; Phillips Andrew N;
Activation and coagulation biomarkers are independent predictors of the development of opportunistic disease in patients with HIV infection.
The Journal of infectious diseases 2009;200(6):973-83.
2009: Cozzi-Lepri Alessandro; Phillips Andrew N; Martinez-Picado Javier; Monforte Antonella d'Arminio; Katlama Christine; Eg Hansen Ann-Brit; Horban Andrzej; Bruun Johann; Clotet Bonaventura; Lundgren Jens D;
Rate of accumulation of thymidine analogue mutations in patients continuing to receive virologically failing regimens containing zidovudine or stavudine: implications for antiretroviral therapy programs in resource-limited settings.
The Journal of infectious diseases 2009;200(5):687-97.
2009: Bower Mark; Fisher Martin; Hill Teresa; Reeves Iain; Walsh John; Orkin Chloe; Phillips Andrew N; Bansi Loveleen; Gilson Richard; Easterbrook Philippa; Johnson Margaret; Gazzard Brian; Leen Clifford; Pillay Deenan; Schwenk Achim; Anderson Jane; Porter Kholoud; Gompels Mark; Sabin Caroline A;
CD4 counts and the risk of systemic non-Hodgkin's lymphoma in individuals with HIV in the UK.
Haematologica 2009;94(6):875-80.
2009: Phillips Andrew N; Gilks Charles; Lundgren Jens D
Cost-effectiveness of strategies for monitoring the response to antiretroviral therapy in resource-limited settings.
Archives of internal medicine 2009;169(9):904; author reply 904-5.
2009: Sabin Caroline A; Phillips Andrew N
Should HIV therapy be started at a CD4 cell count above 350 cells/microl in asymptomatic HIV-1-infected patients?
Current opinion in infectious diseases 2009;22(2):191-7.
2009: Smith C J; Phillips A N; Dauer B; Johnson M A; Lampe F C; Youle M S; Tyrer M; Staszewski S
Factors associated with viral rebound among highly treatment-experienced HIV-positive patients who have achieved viral suppression.
HIV medicine 2009;10(1):19-27.
2009: Sabin C A; Smith C J; Delpech V; Anderson J; Bansi L; Gilson R; Schwenk A; Leen C; Gazzard B; Porter K; Mackie N; Fisher M; Orkin C; Johnson M; Easterbrook P; Hill T; Phillips A N;
The associations between age and the development of laboratory abnormalities and treatment discontinuation for reasons other than virological failure in the first year of highly active antiretroviral therapy.
HIV medicine 2009;10(1):35-43.
2008: Cozzi-Lepri Alessandro; Phillips Andrew N; Clotet Bonaventura; Mocroft Amanda; Ruiz Lidia; Kirk Ole; Lazzarin Adriano; Wiercinska-Drapalo Alicja; Karlsson Anders; Lundgren Jens D;
Detection of HIV drug resistance during antiretroviral treatment and clinical progression in a large European cohort study.
AIDS (London, England) 2008;22(16):2187-98.
2008: Bannister Wendy P; Cozzi-Lepri Alessandro; Clotet Bonaventura; Mocroft Amanda; Kjaer Jesper; Reiss Peter; von Wyl Viktor; Lazzarin Adriano; Katlama Christine; Phillips Andrew N; Ruiz Lidia; Lundgren Jens D;
Transmitted drug resistant HIV-1 and association with virologic and CD4 cell count response to combination antiretroviral therapy in the EuroSIDA Study.
Journal of acquired immune deficiency syndromes (1999) 2008;48(3):324-33.
2008: Lodwick Rebecca K; Smith Colette J; Youle Mike; Lampe Fiona C; Tyrer Mervyn; Bhagani Sanjay; Chaloner Clinton; Sabin Caroline A; Johnson Margaret A; Phillips Andrew N
Stability of antiretroviral regimens in patients with viral suppression.
AIDS (London, England) 2008;22(9):1039-46.
2008: Lundgren Jens D; Babiker Abdel; El-Sadr Wafaa; Emery Sean; Grund Birgit; Neaton James D; Neuhaus Jacquie; Phillips Andrew N
Inferior clinical outcome of the CD4+ cell count-guided antiretroviral treatment interruption strategy in the SMART study: role of CD4+ Cell counts and HIV RNA levels during follow-up.
The Journal of infectious diseases 2008;197(8):1145-55.
2008: Sabin C A; d'Arminio Monforte A; Friis-Moller N; Weber R; El-Sadr W M; Reiss P; Kirk O; Mercie P; Law M G; De Wit S; Pradier C; Phillips A N; Lundgren J D
Changes over time in risk factors for cardiovascular disease and use of lipid-lowering drugs in HIV-infected individuals and impact on myocardial infarction.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2008;46(7):1101-10.
2008: Madge S; Smith C J; Lampe F; Sabin C A; Youle M; Johnson M A; Phillips A N
An audit of viral load in one clinical population to describe features of viraemic patients on antiretroviral therapy.
HIV medicine 2008;9(4):208-13.
2008: Easterbrook P J; Phillips A N; Hill T; Matthias R; Fisher M; Gazzard B; Gilson R; Scullard G; Johnson M; Dunn D T; Orkin C; Anderson J; Schwenk A; Leen C; Sabin C A;
Patterns and predictors of the use of different antiretroviral drug regimens at treatment initiation in the UK.
HIV medicine 2008;9(1):47-56.
2008: Bansi Loveleen K; Benzie Andrew A; Phillips Andrew N; Portsmouth Simon; Hill Teresa; Leen Clifford; Schwenk Achim; Johnson Margaret; Anderson Jane; Gilson Richard; Easterbrook Philippa; Gazzard Brian; Fisher Martin; Orkin Chloe; Porter Kholoud; Pillay Deenan; Taylor Graham P; Walsh John C; Sabin Caroline A;
Are previous treatment interruptions associated with higher viral rebound rates in patients with viral suppression?
AIDS (London, England) 2008;22(3):349-56.
2008: Phillips Andrew N; Carr Andrew; Neuhaus Jacquie; Visnegarwala Fehmida; Prineas Ronald; Burman William J; Williams Ian; Drummond Fraser; Duprez Daniel; Belloso Waldo H; Goebel Frank-Detlef; Grund Birgit; Hatzakis Angelos; Vera Jose; Lundgren Jens D
Interruption of antiretroviral therapy and risk of cardiovascular disease in persons with HIV-1 infection: exploratory analyses from the SMART trial.
Antiviral therapy 2008;13(2):177-87.
2007: Phillips Andrew N; Leen Clifford; Wilson Alan; Anderson Jane; Dunn David; Schwenk Achim; Orkin Chloe; Hill Teresa; Fisher Martin; Walsh John; Pillay Deenan; Bansi Loveleen; Gazzard Brian; Easterbrook Philippa; Gilson Richard; Johnson Margaret; Sabin Caroline A;
Risk of extensive virological failure to the three original antiretroviral drug classes over long-term follow-up from the start of therapy in patients with HIV infection: an observational cohort study.
Lancet 2007;370(9603):1923-8.
2007: Fox Zoe V; Geretti Anna Maria; Kjaer Jesper; Dragsted Ulrik Bak; Phillips Andrew N; Gerstoft Jan; Staszewski Schlomo; Clotet Bonaventura; von Wyl Viktor; Lundgren Jens D
The ability of four genotypic interpretation systems to predict virological response to ritonavir-boosted protease inhibitors.
AIDS (London, England) 2007;21(15):2033-42.
2007: Mocroft Amanda; Ledergerber Bruno; Zilmer Kai; Kirk Ole; Hirschel Bernard; Viard Jean-Paul; Reiss Peter; Francioli Patrick; Lazzarin Adriano; Machala Ladislav; Phillips Andrew N; Lundgren Jens D;
Short-term clinical disease progression in HIV-1-positive patients taking combination antiretroviral therapy: the EuroSIDA risk-score.
AIDS (London, England) 2007;21(14):1867-75.
2007: Smith Colette J; Sabin Caroline A; Youle Mike S; Lampe Fiona C; Bhagani Sanjay; Madge Sara; Puradiredja Dewi; Johnson Margaret A; Phillips Andrew N
Response to efavirenz-containing regimens in previously antiretroviral-naive HIV-positive patients: the role of gender.
Journal of acquired immune deficiency syndromes (1999) 2007;46(1):62-7.
2007: Phillips Andrew N; Gazzard Brian; Gilson Richard; Easterbrook Philippa; Johnson Margaret; Walsh John; Leen Clifford; Fisher Martin; Orkin Chloe; Anderson Jane; Pillay Deenan; Delpech Valerie; Sabin Caroline; Schwenk Achim; Dunn David; Gompels Mark; Hill Teresa; Porter Kholoud; Babiker Abdel;
Rate of AIDS diseases or death in HIV-infected antiretroviral therapy-naive individuals with high CD4 cell count.
AIDS (London, England) 2007;21(13):1717-21.
2007: Mocroft A; Phillips A N; Gatell J; Ledergerber B; Fisher M; Clumeck N; Losso M; Lazzarin A; Fatkenheuer G; Lundgren J D;
Normalisation of CD4 counts in patients with HIV-1 infection and maximum virological suppression who are taking combination antiretroviral therapy: an observational cohort study.
Lancet 2007;370(9585):407-13.
2007: Hoen Bruno; Cooper David A; Lampe Fiona C; Perrin Luc; Clumeck Nathan; Phillips Andrew N; Goh Li-Ean; Lindback Stefan; Sereni Daniel; Gazzard Brian; Montaner Julio; Stellbrink Hans-Jurgen; Lazzarin Adriano; Ponscarme Diane; Staszewski Shlomo; Mathiesen Lars; Smith Don; Finlayson Robert; Weber Rainer; Wegmann Laurence; Janossy George; Kinloch-de Loes Sabine;
Predictors of virological outcome and safety in primary HIV type 1-infected patients initiating quadruple antiretroviral therapy: QUEST GW PROB3005.
Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 2007;45(3):381-90.
2007: Benzie Andrew A; Bansi Loveleen K; Sabin Caroline A; Portsmouth Simon; Hill Teresa; Johnson Margaret; Gilson Richard; Easterbrook Philippa; Gazzard Brian; Fisher Martin; Orkin Chloe; Dunn David; Delpech Valerie; Taylor Graham P; Walsh John C; Phillips Andrew N;
Increased duration of viral suppression is associated with lower viral rebound rates in patients with previous treatment failures.
AIDS (London, England) 2007;21(11):1423-30.
2007: Lampe Fiona C; Smith Colette J; Madge Sara; Kinloch-de Loes Sabine; Tyrer Mervyn; Sabin Caroline A; Chaloner Clinton; Youle Mike; Johnson Margaret A; Phillips Andrew N
Success of clinical care for human immunodeficiency virus infection according to demographic group among sexually infected patients in a routine clinic population, 1999 to 2004.
Archives of internal medicine 2007;167(7):692-700.
2007: Cozzi-Lepri Alessandro; Phillips Andrew N; Ruiz Lidia; Clotet Bonaventura; Loveday Clive; Kjaer Jesper; Mens Helene; Clumeck Nathan; Viksna Ludmila; Antunes Francisco; Machala Ladislav; Lundgren Jens D;
Evolution of drug resistance in HIV-infected patients remaining on a virologically failing combination antiretroviral therapy regimen.
AIDS (London, England) 2007;21(6):721-32.
2007: Fox Zoe; Antunes Francisco; Davey Rick; Gazzard Brian; Klimas Nancy; Labriola Ann; Losso Marcelo; Neaton James D; Phillips Andrew N; Ruxrungtham Kiat; Staszewski Schlomo; Weiss Laurence; Lundgren Jens D
Predictors of CD4 count change over 8 months of follow up in HIV-1-infected patients with a CD4 count>or=300 cells/microL who were assigned to 7.5 MIU interleukin-2.
HIV medicine 2007;8(2):112-23.
2007: Smith C J; Phillips A N; Youle M S; Sabin C A; Lampe F C; Tsintas R; Tyrer M; Johnson M A
Treatment outcomes amongst previously antiretroviral-naïve HIV-infected patients starting lopinavir/ritonavir-containing antiretroviral regimens at the Royal Free Hospital.
HIV medicine 2007;8(1):55-63.
2007: Phillips Andrew N; Gazzard Brian G; Clumeck Nathan; Losso Marcelo H; Lundgren Jens D
When should antiretroviral therapy for HIV be started?
BMJ (Clinical research ed.) 2007;334(7584):76-8.
2007: Mocroft Amanda; Staszewski Schlomo; Weber Rainer; Gatell José; Rockstroh Jurgen; Gasiorowski Jacek; Panos George; Monforte Antonella d'Arminio; Rakhmanova Aza; Phillips Andrew N; Lundgren Jens D;
Risk of discontinuation of nevirapine due to toxicities in antiretroviral-naive and -experienced HIV-infected patients with high and low CD4+ T-cell counts.
Antiviral therapy 2007;12(3):325-33.
2007: Lampe Fiona C; Porter Kholoud; Kaldor John; Law Matthew; Kinloch-de Loes Sabine; Phillips Andrew N;
Effect of transient antiretroviral treatment during acute HIV infection: comparison of the Quest trial results with CASCADE natural history study.
Antiviral therapy 2007;12(2):189-93.
2006: Cozzi-Lepri Alessandro; De Luca Andrea; Phillips Andrew N; Bongiovanni Marco; Di Giambenedetto Simona; Mena Maurizio; Moioli Maria Cristina; Arlotti Massimo; Sighinolfi Laura; Narciso Pasquale; Lichtner Miriam; Cauda Roberto; Monforte Antonella d'Arminio;
A comparison between abacavir and efavirenz as the third drug used in combination with a background therapy regimen of 2 nucleoside reverse-transcriptase inhibitors in patients with initially suppressed viral loads.
The Journal of infectious diseases 2006;194(1):20-8.
2006: Bannister Wendy P; Kirk Ole; Gatell Jose M; Knysz Brygida; Viard Jean-Paul; Mens Helene; Monforte Antonella D'Arminio; Phillips Andrew N; Mocroft Amanda; Lundgren Jens D;
Regional changes over time in initial virologic response rates to combination antiretroviral therapy across Europe.
Journal of acquired immune deficiency syndromes (1999) 2006;42(2):229-37.
2006: Mocroft Amanda; Phillips Andrew N; Ledergerber Bruno; Katlama Christine; Chiesi Antonio; Goebel Frank-Detlef; Knysz Brygioa; Antunes Francisco; Reiss Peter; Lundgren Jens D
Relationship between antiretrovirals used as part of a cART regimen and CD4 cell count increases in patients with suppressed viremia.
AIDS (London, England) 2006;20(8):1141-50.
2006: Lampe Fiona C; Gatell Jose M; Staszewski Schlomo; Johnson Margaret A; Pradier Christian; Gill M John; de Lazzari Elisa; Dauer Brenda; Youle Mike; Fontas Eric; Krentz Hartmut B; Phillips Andrew N
Changes over time in risk of initial virological failure of combination antiretroviral therapy: a multicohort analysis, 1996 to 2002.
Archives of internal medicine 2006;166(5):521-8.
2006: Sabin Caroline A; Smith Colette J; Youle Mike; Lampe Fiona C; Bell Di Robertson; Puradiredja Dewi; Lipman Marc C I; Bhagani Sanjay; Phillips Andrew N; Johnson Margaret A
Deaths in the era of HAART: contribution of late presentation, treatment exposure, resistance and abnormal laboratory markers.
AIDS (London, England) 2006;20(1):67-71.
2006: Fox Zoe; Dragsted Ulrik B; Gerstoft Jan; Phillips Andrew N; Kjaer Jesper; Mathiesen Lars; Youle Mike; Katlama Christine; Hill Andrew; Bruun Johan N; Clumeck Nathan; Dellamonica Pierre; Lundgren Jens D;
A randomized trial to evaluate continuation versus discontinuation of lamivudine in individuals failing a lamivudine-containing regimen: the COLATE trial.
Antiviral therapy 2006;11(6):761-70.
2006: Bannister Wendy P; Ruiz Lidia; Loveday Clive; Vella Stefano; Zilmer Kai; Kjaer Jesper; Knysz Brygida; Phillips Andrew N; Mocroft Amanda;
HIV-1 subtypes and response to combination antiretroviral therapy in Europe.
Antiviral therapy 2006;11(6):707-15.
2006: Mocroft Amanda; Rockstroh Jurgen; Soriano Vincent; Kirk Ole; Viard Jean-Paul; Caplinskas Saulius; Gasiorowski Jacek; Chiesi Antonio; Phillips Andrew N; Lundgren Jens D; EuroSIDA Study Group
Limited but increasing use of treatment for hepatitis C across Europe in patients coinfected with HIV and hepatitis C.
Scandinavian journal of infectious diseases 2006;38(11-12):1092-7.
2006: Mocroft A; Neaton J; Bebchuk J; Staszewski S; Antunes F; Knysz B; Law M; Phillips A N; Lundgren J D;
The feasibility of clinical endpoint trials in HIV infection in the highly active antiretroviral treatment (HAART) era.
Clinical trials (London, England) 2006;3(2):119-32.
2005: Mocroft Amanda; Soriano Vincent; Rockstroh Jurgen; Reiss Peter; Kirk Ole; de Wit Stephane; Gatell Jose; Clotet Bonaventura; Phillips Andrew N; Lundgren Jens D;
Is there evidence for an increase in the death rate from liver-related disease in patients with HIV?
AIDS (London, England) 2005;19(18):2117-25.
2005: Smith Colette J; Phillips Andrew N; Hill Teresa; Fisher Martin; Gazzard Brian; Porter Kholoud; Gilson Richard; Easterbrook Philippa; Matthias Ryanne; Scullard George; Johnson Margaret A; Sabin Caroline A;
The rate of viral rebound after attainment of an HIV load <50 copies/mL according to specific antiretroviral drugs in use: results from a multicenter cohort study.
The Journal of infectious diseases 2005;192(8):1387-97.
2005: Sabin Caroline A; Phillips Andrew N; Yee Thynn Thynn; Griffioen Anja; Lee Christine A
Twenty five years of HIV infection in haemophilic men in Britain: an observational study.
BMJ (Clinical research ed.) 2005;331(7523):997-8.
2005: Mocroft A; Phillips A N; Soriano V; Rockstroh J; Blaxhult A; Katlama C; Boron-Kaczmarska A; Viksna L; Kirk O; Lundgren J D;
Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection.
AIDS research and human retroviruses 2005;21(9):743-52.
2005: Kinloch-de Loes Sabine; Hoen Bruno; Smith Don E; Autran Brigitte; Lampe Fiona C; Phillips Andrew N; Goh Li-Ean; Andersson Jan; Tsoukas Christos; Sonnerborg Anders; Tambussi Giuseppe; Girard Pierre-Marie; Bloch Mark; Battegay Manuel; Carter Nick; El Habib Raphaelle; Theofan Georgia; Cooper David A; Perrin Luc;
Impact of therapeutic immunization on HIV-1 viremia after discontinuation of antiretroviral therapy initiated during acute infection.
The Journal of infectious diseases 2005;192(4):607-17.
2005: Mocroft Amanda; Oancea Cristina; van Lunzen Jan; Vanhems Philippe; Banhegyi Denes; Chiesi Antonio; Vinogradova Elena; Maayan Shlomo; Phillips Andrew N; Lundgren Jens;
Decline in esophageal candidiasis and use of antimycotics in European patients with HIV.
The American journal of gastroenterology 2005;100(7):1446-54.
2005: Mocroft A; Phillips A N; Soriano V; Rockstroh J; Blaxhult A; Katlama C; Boron-Kaczmarska A; Viksna L; Kirk O; Lundgren J D;
Reasons for stopping antiretrovirals used in an initial highly active antiretroviral regimen: increased incidence of stopping due to toxicity or patient/physician choice in patients with hepatitis C coinfection.
AIDS research and human retroviruses 2005;21(6):527-36.
2005: Phillips Andrew N; Dunn David; Sabin Caroline; Pozniak Anton; Matthias Ryanne; Geretti Anna Maria; Clarke John; Churchill Duncan; Williams Ian; Hill Teresa; Green Hannah; Porter Kholoud; Scullard George; Johnson Margaret; Easterbrook Philippa; Gilson Richard; Fisher Martin; Loveday Clive; Gazzard Brian; Pillay Deenan;
Long term probability of detection of HIV-1 drug resistance after starting antiretroviral therapy in routine clinical practice.
AIDS (London, England) 2005;19(5):487-94.
2005: Sabin Caroline A; Hill Teresa; Lampe Fiona; Matthias Ryanne; Bhagani Sanjay; Gilson Richard; Youle Mike S; Johnson Margaret A; Fisher Martin; Scullard George; Easterbrook Philippa; Gazzard Brian; Phillips Andrew N;
Treatment exhaustion of highly active antiretroviral therapy (HAART) among individuals infected with HIV in the United Kingdom: multicentre cohort study.
BMJ (Clinical research ed.) 2005;330(7493):695.
2005: Dorrucci Maria; Phillips Andrew N; Longo Benedetta; Rezza Giovanni;
Changes over time in post-seroconversion CD4 cell counts in the Italian HIV-Seroconversion Study: 1985-2002.
AIDS (London, England) 2005;19(3):331-5.
2005: Cozzi-Lepri Alessandro; Ruiz Lidia; Loveday Clive; Phillips Andrew N; Clotet Bonaventura; Reiss Peter; Ledergerber Bruno; Holkmann Christian; Staszewski Schlomo; Lundgren Jens D;
Thymidine analogue mutation profiles: factors associated with acquiring specific profiles and their impact on the virological response to therapy.
Antiviral therapy 2005;10(7):791-802.
2005: Mocroft Amanda; Rockstroh Jurgen; Soriano Vincent; Ledergerber Bruno; Kirk Ole; Vinogradova Elena; Reiss Peter; Katlama Christine; Phillips Andrew N; Lundgren Jens D;
Are specific antiretrovirals associated with an increased risk of discontinuation due to toxicities or patient/physician choice in patients with hepatitis C virus coinfection?
Antiviral therapy 2005;10(7):779-90.
2005: Colette J Smith; Sabin Caroline A; Lampe Fiona C; Shah Sapna; Tyrer Mervyn; Youle Mike S; Cropley Ian; Johnson Margaret A; Phillips Andrew N
The relationship between CD4 cell count nadirs and the toxicity profiles of antiretroviral regimens.
Antiviral therapy 2005;10(3):459-67.
2004: Mocroft A; Ledergerber B; Viard J P; Staszewski S; Murphy M; Chiesi A; Horban A; Hansen A-B E; Phillips A N; Lundgren J D;
Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group.
The Journal of infectious diseases 2004;190(11):1947-56.
2004: Sabin Caroline A; Smith Colette J; Gumley Helen; Murphy Gabrielle; Lampe Fiona C; Phillips Andrew N; Prinz Beth; Youle Mike; Johnson Margaret A
Late presenters in the era of highly active antiretroviral therapy: uptake of and responses to antiretroviral therapy.
AIDS (London, England) 2004;18(16):2145-51.
2004: Mocroft Amanda; Gatell Jose; Reiss Peter; Ledergerber Bruno; Kirk Ole; Vella Stefano; Blaxhult Anders; Phillips Andrew N; Lundgren Jens;
Causes of death in HIV infection: the key determinant to define the clinical response to anti-HIV therapy.
AIDS (London, England) 2004;18(17):2333-7.
2004: Smith Colette J; Sabin Caroline A; Youle Mike S; Kinloch-de Loes Sabine; Lampe Fiona C; Madge Sara; Cropley Ian; Johnson Margaret A; Phillips Andrew N
Factors influencing increases in CD4 cell counts of HIV-positive persons receiving long-term highly active antiretroviral therapy.
The Journal of infectious diseases 2004;190(10):1860-8.
2004: Cabrera Cecilia; Cozzi-Lepri Alessandro; Phillips Andrew N; Loveday Clive; Kirk Ole; Ait-Khaled Mounir; Reiss Peter; Kjaer Jesper; Ledergerber Bruno; Lundgren Jens D; Clotet Bonaventura; Ruiz Lidia;
Baseline resistance and virological outcome in patients with virological failure who start a regimen containing abacavir: EuroSIDA study.
Antiviral therapy 2004;9(5):787-800.
2004: Smith Colette J; Staszewski Schlomo; Sabin Caroline A; Nelson Mark; Dauer Brenda; Gute Peter; Johnson Margaret A; Phillips Andrew N; Gazzard Brian
Use of viral load measured after 4 weeks of highly active antiretroviral therapy to predict virologic outcome at 24 weeks for HIV-1-positive individuals.
Journal of acquired immune deficiency syndromes (1999) 2004;37(1):1155-9.
2004: Phillips Andrew N; Ledergerber Bruno; Horban Andrezej; Reiss Peter; Chiesi Antonio; Kirk Ole; Mulchany Fiona; Fisher Martin; Machala Ladislav; Lundgren Jens D;
Rate of viral rebound according to specific drugs in the regimen in 2120 patients with HIV suppression.
AIDS (London, England) 2004;18(13):1795-804.
2004: Mocroft Amanda; Kirk Ole; Clumeck Nathan; Gargalianos-Kakolyris Panaglotis; Trocha Hanna; Chentsova Nelly; Antunes Francisco; Stellbrink Hans-Jürgen; Phillips Andrew N; Lundgren Jens D
The changing pattern of Kaposi sarcoma in patients with HIV, 1994-2003: the EuroSIDA Study.
Cancer 2004;100(12):2644-54.
2003: Murri Rita; Lepri Alessandro Cozzi; Phillips Andrew N; Girardi Enrico; Nasti Guglielmo; Ferrara Sergio; Mura Maria Stella; Mussini Cristina; Petrelli Enzo; Arlotti Massimo; De Stefano Carlo; Vigano Paola; Novati Roberto; Cargnel Antonietta; Monforte Antonella D'Arminio;
Access to antiretroviral treatment, incidence of sustained therapy interruptions, and risk of clinical events according to sex: evidence from the I.Co.N.A. Study.
Journal of acquired immune deficiency syndromes (1999) 2003;34(2):184-90.
2003: Phillips Andrew N; Lepri Alessandro Cozzi; Lampe Fiona; Johnson Margaret; Sabin Caroline A
When should antiretroviral therapy be started for HIV infection? Interpreting the evidence from observational studies.
AIDS (London, England) 2003;17(13):1863-9.
2003: Mocroft Amanda; Ruiz Lidia; Reiss Peter; Ledergerber Bruno; Katlama Christine; Lazzarin Adriano; Goebel Frank-Detlef; Phillips Andrew N; Clotet Bonaventura; Lundgren Jens D;
Virological rebound after suppression on highly active antiretroviral therapy.
AIDS (London, England) 2003;17(12):1741-51.
2003: Mocroft A; Ledergerber B; Katlama C; Kirk O; Reiss P; d'Arminio Monforte A; Knysz B; Dietrich M; Phillips A N; Lundgren J D;
Decline in the AIDS and death rates in the EuroSIDA study: an observational study.
Lancet 2003;362(9377):22-9.
2003: Phillips Andrew N; Youle Michael S; Lampe Fiona; Johnson Margaret; Sabin Caroline A; Lepri Alessandro Cozzi; Loveday Clive
Theoretical rationale for the use of sequential single-drug antiretroviral therapy for treatment of HIV infection.
AIDS (London, England) 2003;17(7):1009-16.
2003: Smith Colette J; Sabin Caroline A; Lampe Fiona C; Kinloch-de-Loes Sabine; Gumley Helen; Carroll Anne; Prinz Beth; Youle Mike; Johnson Margaret A; Phillips Andrew N
The potential for CD4 cell increases in HIV-positive individuals who control viraemia with highly active antiretroviral therapy.
AIDS (London, England) 2003;17(7):963-9.
2003: Cozzi-Lepri Alessandro; Phillips Andrew N; Miller Veronica; Katlama Christine; Ledergerber Bruno; Vella Stefano; Weber Jonathan; Bruun Johan N; Kirk Ole; Clotet Bonaventura; Lundgrens Jens D
Changes in viral load in people with virological failure who remain on the same HAART regimen.
Antiviral therapy 2003;8(2):127-36.
2003: Sabin C A; Lampe F C; Chaloner C; Madge S J; Lipman M C I; Youle M; Phillips A N; Johnson M A
An audit of antiretroviral treatment use in HIV-infected patients in a London clinic: the limitations of observational databases when auditing antiretroviral treatment use.
HIV medicine 2003;4(2):87-93.
2003: Moore Antonia L; Kirk Ole; Johnson Anne M; Katlama Christine; Blaxhult Anders; Dietrich Manfred; Colebunders Robert; Chiesi Antonio; Lungren Jens D; Phillips Andrew N;
Virologic, immunologic, and clinical response to highly active antiretroviral therapy: the gender issue revisited.
Journal of acquired immune deficiency syndromes (1999) 2003;32(4):452-61.
2003: Lampe Fiona C; Johnson Margaret A; Lipman Marc; Loveday Clive; Youle Mike; Ransom Darren; Sabin Caroline A; Tyrer Mervyn; Phillips Andrew N
Viral breakthrough after suppression with highly active antiretroviral therapy: experience from 233 individuals with viral loads of less than 50 copies/ml followed for up to 4 years.
AIDS (London, England) 2003;17(5):768-70.
2002: Sabin Caroline A; Griffioen Anja; Yee Thynn Thynn; Emery Vincent C; Herrero-Martinez Esteban; Phillips Andrew N; Lee Christine A
Markers of HIV-1 disease progression in individuals with haemophilia coinfected with hepatitis C virus: a longitudinal study.
Lancet 2002;360(9345):1546-51.
2002: Phillips Andrew N; Staszewski Schlomo; Lampe Fiona; Youle Michael S; Klauke Stephan; Bickel Markus; Sabin Caroline A; Doerr Hans Wilhelm; Johnson Margaret A; Loveday Clive; Miller Veronica;
Human immunodeficiency virus rebound after suppression to <400 copies/mL during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression.
The Journal of infectious diseases 2002;186(8):1086-91.
2002: Phillips Andrew N; Youle Michael; Lampe Fiona; Sabin Caroline A; Hill Andrew; Ransom Darren; Gumley Helen; Loveday Clive; Lipman Marc; Johnson Margaret
CD4 cell count changes in individuals with counts above 500 cells/mm and viral loads below 50 copies/ml on antiretroviral therapy.
AIDS (London, England) 2002;16(7):1073-5.
2002: Barry S M; Lloyd-Owen S J; Madge S J; Cozzi-Lepri A; Evans A J; Phillips A N; Johnson M A
The changing demographics of new HIV diagnoses at a London centre from 1994 to 2000.
HIV medicine 2002;3(2):129-34.
2002: Cozzi-Lepri Alessandro; Phillips Andrew N; d'Arminio Monforte Antonella; Piersantelli Nicolò; Orani Anna; Petrosillo Nicola; Leoncini Francesco; Scerbo Antonio; Tundo Paolo; Abrescia Nicola; Moroni Mauro;
Virologic and immunologic response to regimens containing nevirapine or efavirenz in combination with 2 nucleoside analogues in the Italian Cohort Naive Antiretrovirals (I.Co.N.A.) study.
The Journal of infectious diseases 2002;185(8):1062-9.
2002: Mocroft A; Phillips A N; Friis-Møller N; Colebunders R; Johnson A M; Hirschel B; Saint-Marc T; Staub T; Clotet B; Lundgren J D;
Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study.
Antiviral therapy 2002;7(1):21-30.
2002: Moore Antonia L; Youle Mike; Lipman Marc; Cozzi-Lepri Alessandro; Lampe Fiona; Madge Sarah; Nesaratnam Shrenee; Tyrer Mervyn; Cuthbertson Zoe; Ransom Darren; Loveday Clive; Johnson Margaret A; Phillips Andrew N;
Raised viral load in patients with viral suppression on highly active antiretroviral therapy: transient increase or treatment failure?
AIDS (London, England) 2002;16(4):615-8.
2002: Moore Antonia L; Sabin Caroline A; Johnson Margaret A; Phillips Andrew N
Gender and clinical outcomes after starting highly active antiretroviral treatment: a cohort study.
Journal of acquired immune deficiency syndromes (1999) 2002;29(2):197-202.
2002: Youle Mike; Tyrer Mervyn; Fisher Martin; Lampe Fiona; Wilson Deborah; Ransom Darren; Story Alister; Mocroft Amanda; Loveday Clive; Johnson Margaret A; Phillips Andrew N
Brief report: two-year outcome of a multidrug regimen in patients who did not respond to a protease inhibitor regimen.
Journal of acquired immune deficiency syndromes (1999) 2002;29(1):58-61.
2001: Phillips A N; Pradier C; Lazzarin A; Clotet B; Goebel F D; Hermans P; Antunes F; Ledergerber B; Kirk O; Lundgren J D;
Viral load outcome of non-nucleoside reverse transcriptase inhibitor regimens for 2203 mainly antiretroviral-experienced patients.
AIDS (London, England) 2001;15(18):2385-95.
2001: Phillips A N; Miller V; Sabin C; Cozzi Lepri A; Klauke S; Bickel M; Doerr H W; Hill A; Staszewski S
Durability of HIV-1 viral suppression over 3.3 years with multi-drug antiretroviral therapy in previously drug-naive individuals.
AIDS (London, England) 2001;15(18):2379-84.
2001: Phillips A N; Youle M; Johnson M; Loveday C
Use of a stochastic model to develop understanding of the impact of different patterns of antiretroviral drug use on resistance development.
AIDS (London, England) 2001;15(17):2211-20.
2001: Moore A L; Vashisht A; Sabin C A; Mocroft A; Madge S; Phillips A N; Studd J W; Johnson M A
Reduced bone mineral density in HIV-positive individuals.
AIDS (London, England) 2001;15(13):1731-3.
2001: Sabin C A; Lepri A C; Devereux H; Phillips A N; Loveday C; Lee C A
Relationships among the detection of p24 antigen, human immunodeficiency virus (HIV) RNA level, CD4 cell count, and disease progression in HIV-infected individuals with hemophilia.
The Journal of infectious diseases 2001;184(4):511-4.
2001: Sabin C A; Phillips A N
Cohort studies in sexual health.
Sexually transmitted infections 2001;77(3):174-8.
2001: Kirk O; Mocroft A; Pradier C; Bruun J N; Hemmer R; Clotet B; Miller V; Viard J P; Phillips A N; Lundgren J D;
Clinical outcome among HIV-infected patients starting saquinavir hard gel compared to ritonavir or indinavir.
AIDS (London, England) 2001;15(8):999-1008.
2001: Cozzi Lepri A; Phillips A N; d'Arminio Monforte A; Castelli F; Antinori A; de Luca A; Pezzotti P; Alberici F; Cargnel A; Grima P; Piscopo R; Prestileo T; Scalise G; Vigevani M; Moroni M;
When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study.
AIDS (London, England) 2001;15(8):983-90.
2001: Pezzotti P; Pappagallo M; Phillips A N; Boros S; Valdarchi C; Sinicco A; Zaccarelli M; Rezza G;
Response to highly active antiretroviral therapy according to duration of HIV infection.
Journal of acquired immune deficiency syndromes (1999) 2001;26(5):473-9.
2001: Moore A L; Mocroft A; Madge S; Devereux H; Wilson D; Phillips A N; Johnson M
Gender differences in virologic response to treatment in an HIV-positive population: a cohort study.
Journal of acquired immune deficiency syndromes (1999) 2001;26(2):159-63.
2001: Mocroft A; Phillips A N; Miller V; Gatell J; van Lunzen J; Parkin J M; Weber R; Roge B; Lazzarin A; Lundgren J D;
The use of and response to second-line protease inhibitor regimens: results from the EuroSIDA study.
AIDS (London, England) 2001;15(2):201-9.
2001: Mocroft A; Youle M; Moore A; Sabin C A; Madge S; Lepri A C; Tyrer M; Chaloner C; Wilson D; Loveday C; Johnson M A; Phillips A N
Reasons for modification and discontinuation of antiretrovirals: results from a single treatment centre.
AIDS (London, England) 2001;15(2):185-94.
2001: Lepri A C; Miller V; Phillips A N; Rabenau H; Sabin C A; Staszewski S
The virological response to highly active antiretroviral therapy over the first 24 weeks of therapy according to the pre-therapy viral load and the weeks 4-8 viral load.
AIDS (London, England) 2001;15(1):47-54.
2000: Sabin C A; Lepri A C; Phillips A N
A practical guide to applying the intention-to-treat principle to clinical trials in HIV infection.
HIV clinical trials 2000;1(2):31-8.
2000: Rezza G; Lepri A C; d'Arminio Monforte A; Pezzotti P; Castelli F; Dianzani F; Lazzarin A; De Luca A; Arlotti M; Leoncini F; Manconi P E; Rizzardini G; Minoli L; Poggio A; Ippolito G; Phillips A N; Moroni M
Plasma viral load concentrations in women and men from different exposure categories and with known duration of HIV infection. I.CO.N.A. Study Group.
Journal of acquired immune deficiency syndromes (1999) 2000;25(1):56-62.
2000: Miller V; Sabin C A; Phillips A N; Rottmann C; Rabenau H; Weidmann E; Rickerts V; Findhammer S; Helm E B; Staszewski S
The impact of protease inhibitor-containing highly active antiretroviral therapy on progression of HIV disease and its relationship to CD4 and viral load.
AIDS (London, England) 2000;14(14):2129-36.
2000: Kirk O; Gatell J M; Mocroft A; Pedersen C; Proenca R; Brettle R P; Barton S E; Sudre P; Phillips A N
Infections with Mycobacterium tuberculosis and Mycobacterium avium among HIV-infected patients after the introduction of highly active antiretroviral therapy. EuroSIDA Study Group JD.
American journal of respiratory and critical care medicine 2000;162(3 Pt 1):865-72.
2000: Mocroft A; Gill M J; Davidson W; Phillips A N
Are there gender differences in starting protease inhibitors, HAART, and disease progression despite equal access to care?
Journal of acquired immune deficiency syndromes (1999) 2000;24(5):475-82.
2000: Youle M; Janossy G; Turnbull W; Tilling R; Loveday C; Mocroft A; Tyrer M; Madge S; Wilson D; Dykhoff A; Johnson M; Phillips A N
Changes in CD4 lymphocyte counts after interruption of therapy in patients with viral failure on protease inhibitor-containing regimens. Royal Free Centre for HIV Medicine.
AIDS (London, England) 2000;14(12):1717-20.
2000: Mocroft A; Katlama C; Johnson A M; Pradier C; Antunes F; Mulcahy F; Chiesi A; Phillips A N; Kirk O; Lundgren J D
AIDS across Europe, 1994-98: the EuroSIDA study.
Lancet 2000;356(9226):291-6.
2000: Mocroft A; Devereux H; Kinloch-de-Loes S; Wilson D; Madge S; Youle M; Tyrer M; Loveday C; Phillips A N; Johnson M A
Immunological, virological and clinical response to highly active antiretroviral therapy treatment regimens in a complete clinic population. Royal Free Centre for HIV Medicine.
AIDS (London, England) 2000;14(11):1545-52.
2000: Sabin C A; Yee T T; Devereux H; Griffioen A; Loveday C; Phillips A N; Lee C A
Two decades of HIV infection in a cohort of haemophilic individuals: clinical outcomes and response to highly active antiretroviral therapy.
AIDS (London, England) 2000;14(8):1001-7.
2000: Sabin C A; Devereux H L; Clewley G; Emery V C; Phillips A N; Loveday C; Lee C A; Griffiths P D
Cytomegalovirus seropositivity and human immunodeficiency virus type 1 RNA levels in individuals with hemophilia.
The Journal of infectious diseases 2000;181(5):1800-3.
2000: d'Arminio Monforte A; Lepri A C; Rezza G; Pezzotti P; Antinori A; Phillips A N; Angarano G; Colangeli V; De Luca A; Ippolito G; Caggese L; Soscia F; Filice G; Gritti F; Narciso P; Tirelli U; Moroni M
Insights into the reasons for discontinuation of the first highly active antiretroviral therapy (HAART) regimen in a cohort of antiretroviral naïve patients. I.CO.N.A. Study Group. Italian Cohort of Antiretroviral-Naïve Patients.
AIDS (London, England) 2000;14(5):499-507.
2000: Cozzi Lepri A; Sabin C A; Staszewski S; Hertogs K; Müller A; Rabenau H; Phillips A N; Miller V
Resistance profiles in patients with viral rebound on potent antiretroviral therapy.
The Journal of infectious diseases 2000;181(3):1143-7.
2000: Sabin C A; Devereux H; Phillips A N; Hill A; Janossy G; Lee C A; Loveday C
Course of viral load throughout HIV-1 infection.
Journal of acquired immune deficiency syndromes (1999) 2000;23(2):172-7.
1999: Griffiths P D; Ait-Khaled M; Bearcroft C P; Clark D A; Quaglia A; Davies S E; Burroughs A K; Rolles K; Kidd I M; Knight S N; Noibi S M; Cope A V; Phillips A N; Emery V C
Human herpesviruses 6 and 7 as potential pathogens after liver transplant: prospective comparison with the effect of cytomegalovirus.
Journal of medical virology 1999;59(4):496-501.
1999: Chiesi A; Mocroft A; Dally L G; Miller V; Katlama C; Ledergerber B; Pedersen C; Phillips A N; Arcieri R; Lundgren J D
Regional survival differences across Europe in HIV-positive people: the EuroSIDA study.
AIDS (London, England) 1999;13(16):2281-8.
1999: Mocroft A; Sabin C A; Youle M; Swaden L; Tyrer M; Wilson D; Madge S; Johnson M A; Phillips A N
Changing treatment patterns among patients with HIV: Royal Free Hospital 1987-97.
HIV medicine 1999;1(1):32-9.
1999: Phillips A N; Grabar S; Tassie J M; Costagliola D; Lundgren J D; Egger M
Use of observational databases to evaluate the effectiveness of antiretroviral therapy for HIV infection: comparison of cohort studies with randomized trials. EuroSIDA, the French Hospital Database on HIV and the Swiss HIV Cohort Study Groups.
AIDS (London, England) 1999;13(15):2075-82.
1999: Mocroft A; Sabin C A; Youle M; Madge S; Tyrer M; Devereux H; Deayton J; Dykhoff A; Lipman M C; Phillips A N; Johnson M A
Changes in AIDS-defining illnesses in a London Clinic, 1987-1998.
Journal of acquired immune deficiency syndromes (1999) 1999;21(5):401-7.
1999: Miller V; Staszewski S; Sabin C; Carlebach A; Rottmann C; Weidmann E; Rabenau H; Hill A; Lepri A C; Phillips A N
CD4 lymphocyte count as a predictor of the duration of highly active antiretroviral therapy-induced suppression of human immunodeficiency virus load.
The Journal of infectious diseases 1999;180(2):530-3.
1999: Mocroft A; Barry S; Sabin C A; Lepri A C; Kinloch S; Drinkwater A; Lipman M; Youle M; Johnson M A; Phillips A N
The changing pattern of admissions to a London hospital of patients with HIV: 1988-1997. Royal Free Centre for HIV Medicine.
AIDS (London, England) 1999;13(10):1255-61.
1999: Weverling G J; Mocroft A; Ledergerber B; Kirk O; Gonzáles-Lahoz J; d'Arminio Monforte A; Proenca R; Phillips A N; Lundgren J D; Reiss P
Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. EuroSIDA Study Group.
Lancet 1999;353(9161):1293-8.
1999: Emery V C; Atkins M C; Bowen E F; Clark D A; Johnson M A; Kidd I M; McLaughlin J E; Phillips A N; Strappe P M; Griffiths P D
Interactions between beta-herpesviruses and human immunodeficiency virus in vivo: evidence for increased human immunodeficiency viral load in the presence of human herpesvirus 6.
Journal of medical virology 1999;57(3):278-82.
1999: Miller V; Staszewski S; Nisius G; Lepri A C; Sabin C; Phillips A N
Risk of new AIDS diseases in people on triple therapy.
Lancet 1999;353(9151):463.
1999: Petruckevitch A; Del Amo J; Phillips A N; Stephenson J M; Johnson A M; De Cock K M
Risk of cancer in patients with HIV disease. London African HIV/AIDS Study Group.
International journal of STD & AIDS 1999;10(1):38-42.
1999: Phillips A N; McLean A R; Loveday C; Tyrer M; Bofill M; Devereux H; Madge S; Dykoff A; Drinkwater A; Burke A; Huckett L; Janossy G; Johnson M A
In vivo HIV-1 replicative capacity in early and advanced infection.
AIDS (London, England) 1999;13(1):67-73.
1999: Del Amo J; Petruckevitch A; Phillips A N; De Cock K M; Stephenson J; Desmond N; Hanscheid T; Low N; Newell A; Obasi A; Paine K; Pym A; Theodore C; Johnson A M
Risk factors for tuberculosis in patients with AIDS in London: a case-control study.
The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease 1999;3(1):12-7.
1998: Madge S; Phillips A N; Griffioen A; Olaitan A; Johnson M A
Demographic, clinical and social factors associated with human immunodeficiency virus infection and other sexually transmitted diseases in a cohort of women from the United Kingdom and Ireland. MRC Collaborative Study of women with HIV.
International journal of epidemiology 1998;27(6):1068-71.
1998: Staszewski S; Miller V; Sabin C; Berger A; Hill A M; Phillips A N
Rebound of HIV-1 viral load after suppression to very low levels.
AIDS (London, England) 1998;12(17):2360.
1998: Mocroft A; Vella S; Benfield T L; Chiesi A; Miller V; Gargalianos P; d'Arminio Monforte A; Yust I; Bruun J N; Phillips A N; Lundgren J D
Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Group.
Lancet 1998;352(9142):1725-30.
1998: Mocroft A; Gill M J; Davidson W; Phillips A N
Predictors of a viral response and subsequent virological treatment failure in patients with HIV starting a protease inhibitor.
AIDS (London, England) 1998;12(16):2161-7.
1998: Sabin C A; Mocroft A; Bofill M; Janossy G; Lee C A; Johnson M; Phillips A N
Changes in lymphocyte subsets in human immunodeficiency virus-positive persons with < 5 CD4 T lymphocytes/mm3.
The Journal of infectious diseases 1998;178(4):1166-9.
1998: Cozzi Lepri A; Katzenstein T L; Ullum H; Phillips A N; Skinhøj P; Gerstoft J; Pedersen B K
The relative prognostic value of plasma HIV RNA levels and CD4 lymphocyte counts in advanced HIV infection.
AIDS (London, England) 1998;12(13):1639-43.
1998: Cozzi Lepri A; Phillips A N; Pezzotti P; Mocroft A; Sabin C A; Porter K; Rezza G
Evaluating the effect of year of seroconversion on HIV progression in cohort studies. Italian Seroconversion Study.
AIDS (London, England) 1998;12(11):1353-60.
1998: Sabin C A; Devereux H; Phillips A N; Janossy G; Loveday C; Lee C A
Immune markers and viral load after HIV-1 seroconversion as predictors of disease progression in a cohort of haemophilic men.
AIDS (London, England) 1998;12(11):1347-52.
1998: Cozzi Lepri A; Smith G D; Mocroft A; Sabin C A; Morris R W; Phillips A N
A practical approach to adjusting for attrition bias in HIV clinical trials with serial marker responses.
AIDS (London, England) 1998;12(10):1155-61.
1998: Petruckevitch A; Del Amo J; Phillips A N; Johnson A M; Stephenson J; Desmond N; Hanscheid T; Low N; Newell A; Obasi A; Paine K; Pym A; Theodore C; De Cock K M
Disease progression and survival following specific AIDS-defining conditions: a retrospective cohort study of 2048 HIV-infected persons in London.
AIDS (London, England) 1998;12(9):1007-13.
1998: Wannamethee S G; Sirivichayakul S; Phillips A N; Ubolyam S; Ruxrungtham K; Hanvanich M; Phanuphak P
Clinical and immunological features of human immunodeficiency virus infection in patients from Bangkok, Thailand.
International journal of epidemiology 1998;27(2):289-95.
1998: Mocroft A; Youle M; Phillips A N; Halai R; Easterbrook P; Johnson M A; Gazzard B
The incidence of AIDS-defining illnesses in 4883 patients with human immunodeficiency virus infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group.
Archives of internal medicine 1998;158(5):491-7.
1998: Phillips A N; Katlama C; Barton S; Vella S; Blaxhult A; Clotet B; Goebel F D; Hirschel B; Pedersen C; Lundgren J D
Survival in 2367 zidovudine-treated patients according to use of other nucleoside analogue drugs. The EuroSIDA Study Group.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1998;17(3):239-44.
1997: Alliegro M B; Dorrucci M; Phillips A N; Pezzotti P; Boros S; Zaccarelli M; Pristerà R; Rezza G
Incidence and consequences of pregnancy in women with known duration of HIV infection. Italian Seroconversion Study Group.
Archives of internal medicine 1997;157(22):2585-90.
1997: Sabin C A; Bofill M; Phillips A N; Elford J; Janossy G; Lee C A
Relation between soluble CD30 levels measured soon after HIV seroconversion and disease progression in men with hemophilia.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1997;16(4):279-83.
1997: Cozzi Lepri A; Phillips A N; Pezzotti P; Rezza G
Is the clinical course of HIV infection changing? Study's censoring strategy may be source of bias.
BMJ (Clinical research ed.) 1997;315(7117):1237.
1997: Phillips A N; McLean A; Johnson M A; Tyrer M; Emery V; Griffiths P; Bofill M; Janossy G; Loveday C
HIV-1 dynamics after transient antiretroviral therapy: implications for pathogenesis and clinical management.
Journal of medical virology 1997;53(3):261-5.
1997: Cozzi Lepri A; Sabin C A; Phillips A N
Investigating temporal changes in the rate of HIV progression: challenges and limitations.
AIDS (London, England) 1997;11(13):1647-9.
1997: Sabin C A; Mocroft A; Bofill M; Janossy G; Johnson M; Lee C A; Phillips A N
Survival after a very low (< 5 x 10(6)/l) CD4+ T-cell count in individuals infected with HIV.
AIDS (London, England) 1997;11(9):1123-7.
1997: Mocroft A J; Lundgren J D; d'Armino Monforte A; Ledergerber B; Barton S E; Vella S; Katlama C; Gerstoft J; Pedersen C; Phillips A N
Survival of AIDS patients according to type of AIDS-defining event. The AIDS in Europe Study Group.
International journal of epidemiology 1997;26(2):400-7.
1997: Lepri A C; Sabin C A; Pezzotti P; England P D; Phillips A N; Rezza G
Is there a general tendency for CD4 lymphocyte decline to speed up during human immunodeficiency virus infection? Evidence from the Italian Seroconversion Study.
The Journal of infectious diseases 1997;175(4):775-80.
1997: Dorrucci M; Pezzotti P; Phillips A N; Alliegro M B; Rezza G
Antiretroviral treatment and progression to AIDS in HIV seroconverters from different risk groups. HIV Italian Seroconversion Study.
AIDS (London, England) 1997;11(4):461-7.
1997: Phillips A N; Mocroft A; Sabin C A; Cozzi Lepri A
Cross-sectional studies in AIDS pathogenesis: how far can they mislead us?
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1997;14(2):153-7.
1997: Mocroft A; Youle M; Morcinek J; Sabin C A; Gazzard B; Johnson M A; Phillips A N
Survival after diagnosis of AIDS: a prospective observational study of 2625 patients. Royal Free/Chelsea and Westminster Hospitals Collaborative Group.
BMJ (Clinical research ed.) 1997;314(7078):409-13.
1997: Phillips A N; Eron J; Bartlett J; Kuritzkes D R; Johnson V A; Gilbert C; Johnson J; Keller A; Hill A M
Correspondence between the effect of zidovudine plus lamivudine on plasma HIV level/CD4 lymphocyte count and the incidence of clinical disease in infected individuals. North American Lamivudine HIV Working Group.
AIDS (London, England) 1997;11(2):169-75.
1997: Sabin C A; Telfer P; Phillips A N; Bhagani S; Lee C A
The association between hepatitis C virus genotype and human immunodeficiency virus disease progression in a cohort of hemophilic men.
The Journal of infectious diseases 1997;175(1):164-8.
1996: Del Amo J; Petruckevitch A; Phillips A N; Johnson A M; Stephenson J M; Desmond N; Hanscheid T; Low N; Newell A; Obasi A; Paine K; Pym A; Theodore C M; De Cock K M
Spectrum of disease in Africans with AIDS in London.
AIDS (London, England) 1996;10(13):1563-9.
1996: Phillips A N; Sabin C A; Elford J; Bofill M; Timms A; Janossy G; Lee C A
Serum beta 2-microglobulin at HIV-1 seroconversion as a predictor of severe immunodeficiency during 10 years of followup.
Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association 1996;13(3):262-6.
1996: Phillips A N; Lazzarin A; Gonzales-Lahoz J; Clumeck N; Glauser M P; Proenca R; Banhegyi D; Pedersen C; Lundgren J D; Johnson A M
Factors associated with the CD4+ lymphocyte count at diagnosis of acquired immunodeficiency syndrome. The AIDS IN EUROPE Study Group.
Journal of clinical epidemiology 1996;49(11):1253-8.
1996: Phillips A N; Wannamethee S G; Walker M; Thomson A; Smith G D
Life expectancy in men who have never smoked and those who have smoked continuously: 15 year follow up of large cohort of middle aged British men.
BMJ (Clinical research ed.) 1996;313(7062):907-8.
1996: Mocroft A; Youle M; Gazzard B; Morcinek J; Halai R; Phillips A N
Anti-herpesvirus treatment and risk of Kaposi's sarcoma in HIV infection. Royal Free/Chelsea and Westminster Hospitals Collaborative Group.
AIDS (London, England) 1996;10(10):1101-5.
1996: Phillips A N; Smith G D; Johnson M A
Will we ever know when to treat HIV infection?
BMJ (Clinical research ed.) 1996;313(7057):608-10.
1996: Pezzotti P; Phillips A N; Dorrucci M; Lepri A C; Galai N; Vlahov D; Rezza G
Category of exposure to HIV and age in the progression to AIDS: longitudinal study of 1199 people with known dates of seroconversion. HIV Italian Seroconversion Study Group.
BMJ (Clinical research ed.) 1996;313(7057):583-6.
1996: Phillips A N; Eron J J; Bartlett J A; Rubin M; Johnson J; Price S; Self P; Hill A M
HIV-1 RNA levels and the development of clinical disease. North American Lamivudine HIV Working Group.
AIDS (London, England) 1996;10(8):859-65.
1996: Bofill M; Mocroft A; Lipman M; Medina E; Borthwick N J; Sabin C A; Timms A; Winter M; Baptista L; Johnson M A; Lee C A; Phillips A N; Janossy G
Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients.
AIDS (London, England) 1996;10(8):827-34.
1996: Olaitan A; Madge S; McCarthy K H; Phillips A N; Johnson M A
Unrecognised HIV infection among gynaecology patients.
British journal of obstetrics and gynaecology 1996;103(5):470-3.
1996: Anderson J; Melville R; Jeffries D J; Norman J; Welch J; Graham D; Fadojutimi M; Forster G; Phillips M; Sampson K; Kitchen V; Wells C; Byrne G; Mercey D E; Allason-Jones E; Campbell L; French R; Woronowski H; Griffioen A; Stephenson J M; Phillips A N; Keenlyside R; Johnson A M; Barton S; Chard S Harindra V
Ethnic differences in women with HIV infection in Britain and Ireland. The study group for the mrc collaborative study of HIV infection in women.
AIDS (London, England) 1996;10(1):89-93.
1996: Sabin C A; Phillips A N; Lee C A
Response: arguments contradict the "foreign protein-zidovudine" hypothesis.
BMJ (Clinical research ed.) 1996;312(7025):211-2.
1996: Sabin C A; Pasi K J; Phillips A N; Lilley P; Bofill M; Lee C A
Comparison of immunodeficiency and AIDS defining conditions in HIV negative and HIV positive men with haemophilia A.
BMJ (Clinical research ed.) 1996;312(7025):207-10.
1996: Phillips A N
Reduction of HIV concentration during acute infection: independence from a specific immune response.
Science (New York, N.Y.) 1996;271(5248):497-9.
1995: Dorrucci M; Pezzotti P; Phillips A N; Lepri A C; Rezza G
Coinfection of hepatitis C virus with human immunodeficiency virus and progression to AIDS. Italian Seroconversion Study.
The Journal of infectious diseases 1995;172(6):1503-8.
1995: Cozzi Lepri A; Pezzotti P; Phillips A N; Petrucci A; Rezza G
Clinical staging system for AIDS patients.
Lancet 1995;346(8982):1103.
1995: Lundgren J D; Barton S E; Katlama C; Ledergerber B; González-Lahoz J; Pinching A J; Proenca R; Hemmer R; Pedersen C; Phillips A N
Changes in survival over time after a first episode of Pneumocystis carinii pneumonia for European patients with acquired immunodeficiency syndrome. Multicentre Study Group on AIDS in Europe.
Archives of internal medicine 1995;155(8):822-8.
1995: Sabin C A; Phillips A N; Lee C A; Janossy G; Emery V; Griffiths P D
The effect of CMV infection on progression of human immunodeficiency virus disease is a cohort of haemophilic men followed for up to 13 years from seroconversion.
Epidemiology and infection 1995;114(2):361-72.
1994: Cozzi Lepri A; Pezzotti P; Dorrucci M; Phillips A N; Rezza G
HIV disease progression in 854 women and men infected through injecting drug use and heterosexual sex and followed for up to nine years from seroconversion. Italian Seroconversion Study.
BMJ (Clinical research ed.) 1994;309(6968):1537-42.
1994: Phillips A N; Pezzotti P; Lepri A C; Rezza G
CD4 lymphocyte count as a determinant of the time from HIV seroconversion to AIDS and death from AIDS: evidence from the Italian Seroconversion Study.
AIDS (London, England) 1994;8(9):1299-305.
1994: Phillips A N; Antunes F; Stergious G; Ranki A; Jensen G F; Bentwich Z; Sacks T; Pedersen C; Lundgren J D; Johnson A M
A sex comparison of rates of new AIDS-defining disease and death in 2554 AIDS cases. AIDS in Europe Study Group.
AIDS (London, England) 1994;8(6):831-5.
1994: Phillips A N; Smith G D
Cigarette smoking as a potential cause of cervical cancer: has confounding been controlled?
International journal of epidemiology 1994;23(1):42-9.
1994: Sabin C A; Phillips A N; Lee C A; Elford J; Timms A; Bofill M; Janossy G
Beta-2 microglobulin as a predictor of prognosis in HIV-infected men with haemophilia: a proposed strategy for use in clinical care.
British journal of haematology 1994;86(2):366-71.
1993: Phillips A N; Smith G D
The design of prospective epidemiological studies: more subjects or better measurements?
Journal of clinical epidemiology 1993;46(10):1203-11.
1993: Phillips A N; Sabin C A; Elford J; Bofill M; Lee C A; Janossy G
CD8 lymphocyte counts and serum immunoglobulin A levels early in HIV infection as predictors of CD4 lymphocyte depletion during 8 years of follow-up.
AIDS (London, England) 1993;7(7):975-80.
1993: Janossy G; Borthwick N; Lomnitzer R; Medina E; Squire S B; Phillips A N; Lipman M; Johnson M A; Lee C; Bofill M
Lymphocyte activation in HIV-1 infection. I. Predominant proliferative defects among CD45R0+ cells of the CD4 and CD8 lineages.
AIDS (London, England) 1993;7(5):613-24.
1992: Phillips A N; Elford J; Sabin C; Bofill M; Janossy G; Lee C A
Immunodeficiency and the risk of death in HIV infection.
JAMA : the journal of the American Medical Association 1992;268(19):2662-6.
1992: Bofill M; Janossy G; Lee C A; MacDonald-Burns D; Phillips A N; Sabin C; Timms A; Johnson M A; Kernoff P B
Laboratory control values for CD4 and CD8 T lymphocytes. Implications for HIV-1 diagnosis.
Clinical and experimental immunology 1992;88(2):243-52.
1992: Phillips A N; Lee C A; Elford J; Janossy G; Kernoff P B
The cumulative risk of AIDS as the CD4 lymphocyte count declines.
Journal of acquired immune deficiency syndromes 1992;5(2):148-52.
1991: Phillips A N; Lee C A; Elford J; Webster A; Janossy G; Griffiths P D; Kernoff P B
p24 antigenaemia, CD4 lymphocyte counts and the development of AIDS.
AIDS (London, England) 1991;5(10):1217-22.
1991: Shaper A G; Phillips A N; Pocock S J; Walker M; Macfarlane P W
Risk factors for stroke in middle aged British men.
BMJ (Clinical research ed.) 1991;302(6785):1111-5.
1991: Phillips A N; Lee C A; Elford J; Janossy G; Timms A; Bofill M; Kernoff P B
Serial CD4 lymphocyte counts and development of AIDS.
Lancet 1991;337(8738):389-92.
1991: Phillips A N; Smith G D
How independent are "independent" effects? Relative risk estimation when correlated exposures are measured imprecisely.
Journal of clinical epidemiology 1991;44(11):1223-31.
1991: Phillips A N; Lee C A; Elford J; Webster A; Janossy G; Timms A; Bofill M; Kernoff P B
More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts.
Journal of acquired immune deficiency syndromes 1991;4(10):970-5.
1990: Whincup P H; Cook D G; Phillips A N; Shaper A G
ABO blood group and ischaemic heart disease in British men.
BMJ (Clinical research ed.) 1990;300(6741):1679-82.
1989: Walker M; Shaper A G; Phillips A N; Cook D G
Short stature, lung function and risk of a heart attack.
International journal of epidemiology 1989;18(3):602-6.
1989: Phillips A N; Pocock S J
Sample size requirements for prospective studies, with examples for coronary heart disease.
Journal of clinical epidemiology 1989;42(7):639-48.

Sign-in to see more

Sign-in free and Explore the Exciting World of BiomedExperts:

NetworkView

Andrew Phillips

Research Profile (preview)

Disorders

Procedures

Concepts & Ideas

Chemicals & Drugs

Living Beings

Physiology

Phenomena

Network (preview)

Publications

Sign in free and see...

Visualized networks:

GeoTargeted Searches:

Research Profiles:

Geonetwork of Andrew Phillips (preview)

All Publications